Oncology biotech company CytomX has appointed Michael Kavanaugh as chief scientific officer and head of research and early development.
The company has also appointed Sridhar Viswanathan as vice president of process sciences and manufacturing operations and Danielle Olander as vice president of human resources.
Prior to being appointed at CytomX, Dr Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics (Nasdaq: FPRX). Before this, he was vice president of Novartis Vaccines & Diagnostics (NOVN: VX).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze